Ixazomib Plus Cyclo/Dex in Newly Diagnosed MM

December 5-8, 2015; Orlando, Florida
First all-oral proteasome inhibitor–based combination showed promising efficacy and manageable toxicity in untreated MM.
Format: Microsoft PowerPoint (.ppt)
File Size: 553 KB
Released: December 8, 2015

Acknowledgements

Educational grant provided by:
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics
Takeda Oncology

Related Content

Drs. John Burke and Jeff Sharman discuss practice-changing presentations in CLL and lymphomas from the ASH 2018 annual meeting in San Diego.

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 3.5 AMA PRA Category 1 Credits Released: February 14, 2019 Expiration: February 13, 2020

Expert guidance on using newly approved drugs for individualized treatment of patients with acute myeloid leukemia (AML).

Eunice S. Wang, MD Released: February 12, 2019

Expert guidance on using newly approved drugs for individualized treatment of patients with acute myeloid leukemia (AML).

Eunice S. Wang, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 12, 2019 Expiration: February 11, 2020

Expert answers to key questions on the current treatment of Hodgkin lymphoma from a Clinical Care Options symposium in December 2018.

Robert W. Chen, MD Joseph M. Connors, MD, FRCPC Andrew M. Evens, DO, MSc, FACP Released: February 7, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?